Evidence map›Paper›PMID 30773486›Full record

ArticleStem cell reports2019

A Double Fail-Safe Approach to Prevent Tumorigenesis and Select Pancreatic β Cells from Human Embryonic Stem Cells.

Mirza Muhammad Fahd Qadir, Silvia Álvarez-Cubela, Kinsley Belle, Tamar Sapir, Fanuel Messaggio, Kevin B Johnson, Oliver Umland, Darrell Hardin, Dagmar Klein, Ingrid Pérez-Álvarez and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Benefits and Hurdles of Pancreatic β-Cell Replacement.Stem cells translational medicine · 2022
    Review
  6. Review
  7. Pancreatic β-Cell Development and Regeneration.Cold Spring Harbor perspectives in biology · 2022
    Review
  8. Review
  9. Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes.Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Cell-Based Therapeutic Approaches for Cystic Fibrosis.International journal of molecular sciences · 2020
    Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Mirza Muhammad Fahd QadirDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL, USA.
Silvia Álvarez-CubelaDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Kinsley BelleDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Tamar SapirDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Fanuel MessaggioDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Kevin B JohnsonDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Oliver UmlandDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Darrell HardinDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Dagmar KleinDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Ingrid Pérez-ÁlvarezUniversity of California Irvine Medical Center, Orange, CA 92868, USA.
Fatima SadiqCenter for Specialized Surgery, Florida Hospital, Orlando, FL 32804, USA.
Oscar AlcázarDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Luca A InverardiDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Miami Miller School of Medicine, Miami, FL, USA.
Camillo RicordiDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Biomedical Engineering, University of Miami Miller School of Medicine, Miami, FL, USA.
Peter BuchwaldDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA.
Christopher A FrakerDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Biomedical Engineering, University of Miami Miller School of Medicine, Miami, FL, USA.
Ricardo L PastoriDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Miami Miller School of Medicine, Miami, FL, USA.
Juan Domínguez-BendalaDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL, USA; Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: jdominguez2@med.miami.edu.
University of Miami · USAdventHealth Orlando · USUniversity of California, Irvine Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transplantation of human embryonic stem cell (hESC)-derived insulin-producing β cells for the treatment of diabetes is finally approaching the clinical stage. However, even with state-of-the-art differentiation protocols, a significant percentage of undefined non-endocrine cell types are still generated. Most importantly, there is the potential for carry-over of non-differentiated cell types that may produce teratomas. We sought to modify hESCs so that their differentiated progeny could be selectively devoid of tumorigenic cells and enriched for cells of the desired phenotype (in this case, β cells). Here we report the generation of a modified hESC line harboring two suicide gene cassettes, whose expression results in cell death in the presence of specific pro-drugs. We show the efficacy of this system at enriching for β cells and eliminating tumorigenic ones both in vitro and in vivo. Our approach is innovative inasmuch as it allows for the preservation of the desired cells while eliminating those with the potential to develop teratomas.

Indexed as

AnimalsCarcinogenesisCell DifferentiationCell LineHuman Embryonic Stem CellsHumansInsulin-Secreting CellsMiceMice, Inbred NODMice, SCIDTeratomabeta cell differentiationhuman embryonic stem cellssuicide genesteratomatransplantation

Identifiers

PMID30773486
PMCPMC6409439
OpenAlexW2914684049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.